<DOC>
	<DOC>NCT00563706</DOC>
	<brief_summary>The primary purpose of this protocol is to establish the efficacy, safety, and tolerability of vabicaserin (SCA-136) using a once a day capsule in subjects with acute exacerbations of schizophrenia.</brief_summary>
	<brief_title>Study Evaluating Vabicaserin in Subjects With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Generally healthy, men and women, aged 18 to 65. Hospitalization because of an acute exacerbation of schizophrenia with a diagnosis of schizophrenia established greater than 1 year. Ability to remain hospitalized for the duration of the screening period and for 4 weeks of doubleblind treatment. Current Axis I primary psychiatric diagnosis other than schizophrenia (DSMIVTR criteria). Current diagnosis or history of substance abuse or dependence (DSMIVTR criteria), including alcohol (except for nicotine), within 3 months before baseline (day 1). Subjects taking high or chronic doses of benzodiazepine at the screening evaluation who, in the investigator's judgment, would be likely to have severe withdrawal symptoms upon discontinuation.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>